Contrasting Clarus Therapeutics (OTCMKTS:CRXTQ) & Quince Therapeutics (NASDAQ:QNCX)

Clarus Therapeutics (OTCMKTS:CRXTQ) and Quince Therapeutics (NASDAQ:QNCX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Institutional and Insider Ownership

30.8% of Quince Therapeutics shares are held by institutional investors. 5.3% of Clarus Therapeutics shares are held by insiders. Comparatively, 16.8% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Clarus Therapeutics and Quince Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clarus Therapeutics	0	0	0	0	0.00
Quince Therapeutics	0	0	4	2	3.33

Quince Therapeutics has a consensus price target of $9.50, suggesting a potential upside of 533.33%. Given Quince Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Clarus Therapeutics.

Profitability

This table compares Clarus Therapeutics and Quince Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clarus Therapeutics	N/A	N/A	N/A
Quince Therapeutics	N/A	-53.27%	-22.73%

Earnings & Valuation

This table compares Clarus Therapeutics and Quince Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clarus Therapeutics	N/A	N/A	N/A	N/A	N/A
Quince Therapeutics	N/A	N/A	-$31.39 million	($1.24)	-1.21

Summary

Quince Therapeutics beats Clarus Therapeutics on 6 of the 8 factors compared between the two stocks.

About Clarus Therapeutics

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

About Quince Therapeutics

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.